Organophosphate nerve agents

Handbook of Toxicology of Chemical Warfare Agents

Volumn , Issue , 2009, Pages 43-67

  Watson, Annetta ^a   Opresko, Dennis ^a   Young, Robert ^a   Hauschild, Veronique ^b   King, Joseph ^c   Bakshi, Kulbir ^d  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b U S ARMY CENTER FOR HEALTH PROMOTION AND PREVENTIVE MEDICINE   (United States)

^c U S ARMY   (United States)

^d NATIONAL RESEARCH COUNCIL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349254910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374484-5.00006-7     Document Type: Chapter

References (203)

1. Aas P., Veiteberg T.A., Fonnum F. Acute and sub-acute inhalation of an organophosphate induced alteration of cholinergic muscarinic receptors. Biochem. Pharmacol 1987, 36:1261-1266.
2. Abercrombie P.L. Physical property data review of selected chemical agents and related compounds: Updating Field Manual 3-9 (FM 3-9). ECBC-TR-294. Edgewood Chemical Biological Center, US Army Soldier and Biological Chemical Command, Aberdeen Proving Ground, MD 2003.
3. Abernathy C.O., Donohue J.M., Cicmanec J., Poirier K.A. Some comments on the selection of human intraspecies uncertainty factors. Hum. Ecol. Risk Assess. 2004, 10:29-37.
4. Abou-Donia M.B. The cytoskeleton as a target for organophosphorous ester-induced delayed neurotoxicity (OPIDN). Chem. Biol. Interact. 1993, 87:383-393.
5. Abou-Donia M.B. Organophosphorous ester-induced chronic neurotoxicity. Arch. Environ. Health 2003, 58:484-497.
6. Agency for Toxic Substances and Disease Registry (ATSDR) (2007). Medical Management Guidelines for Nerve Agents: Tabun (GA), Sarin (GB) Soman (GD) and VX. US Department. of Health and Human Services, Washington, DC (updated 24 Sept 2007). http://www.atsdr.cdc.gov/MHMI/mmg166.html.
7. Albuquerque E.X., Pereira E.F., Aracava Y., Fawcett W.P., Oliveira M., Randall W.R., Hamilton T.A., Kan R.K., Romano J.A., Adler M. Effective countermeasures against poisoning by organophosphorous insecticides and nerve agents. Proc. Natl. Acad. Sci. USA 2006, 103:13220-13225.
8. Allon N., Rabinovitz I., Manistersky E., Weissman B.A., Grauer E. Acute and long-lasting cardiac changes following a single whole-body exposure to sarin vapor in rats. Toxicol. Sci. 2005, 87:385-390.
9. Anthony, J.S., Haley, M.V., Manthei, J.H., Way, R.A., Burnett, D.C., Gaviola, B.D., Sommerville, D.R. et al. (2003). Inhalation toxicity of GF vapor in rats as a function of exposure concentration and duration and its potency comparison to GB. ECBC-TR-335. Edgewood Chemical Biological Center, US Army Soldier and Biological Chemical Command, Aberdeen Proving Ground, MD.
10. Anthony J.S., Haley M., Manthei J., Way R., Burnett D., Gaviola B., Sommerville D., et al. Inhalation toxicity of cyclosarin (GF) vapor in rats as a function of exposure concentration and duration: potency comparison to sarin (GB). Inhal. Toxicol. 2004, 16:103-111.
11. Antonijevic B., Stojiljkovic M.P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 2007, 5:71-82.
12. Bajgar J., Bartosova L., Kuca K., Jun D., Fusek J. Changes in cholinesterase activities in the rat blood and brain after sarin intoxication pretreated with butyrylcholinesterase. Drug Chem. Toxicol. 2007, 30:351-359.
13. Baker D.J., Sedgwick E.M. Single fibre electromyographic changes in man after organophosphate exposure. Hum. Exp. Toxicol 1996, 15:369-375.
14. Bakry N.M., El-Rashidy A.H., Eldefawi A.T., Eldefawi M.E. Direct action of organophosphate anticholinesterases on nicotinic and muscarinic acetylcholine receptors. J. Biochem. Toxicol 1988, 3:235-259.
15. Review of the Army's health risk assessments for oral exposure to six chemical-warfare agents. J. Toxicol. Environ. Health, Part A 2000, 59:281-526. K.S. Bakshi, S.N.J. Pang, R. Snyder (Eds.).
16. Bartosova-Sevelova L., Bajgar J. Changes of acetylcholinesterase activity after long-term exposure to sarin vapors in rats. Hum. Exp. Toxicol. 2005, 24:363-367.
17. Bates H.K., LaBorde J.B., Dacre J.C., Young J.F. Developmental toxicity of soman in rats and rabbits. Teratology 1990, 42:15-23.
18. Benton, B.J., Sommerville, D.R., Scotto, J., Burnett, D.C., Gaviola, B.I., Crosier, R.B., Jakubowski, E.M., Jr. et al. (2005). Low-level effects of VX vapor exposure on pupil size and cholinesterase levels in rats. Technical Report ECBC TR-428, US Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD.
19. Benton, B.J., Sommerville, D.R., Anthony, S., Crosier, R.B., Jakubowski, E.M., Whalley, C.E., Dabisch, P.A. et al. (2006a). Low-level effects of VX vapor exposure on pupil size and cholinesterase levels in rats. In Inhalation Toxicology, 2nd edition (H.A. Salem, S.A. Katz, eds), pp. 91-108. CRC Press, Taylor and Francis, Boca Raton, FL.
20. Benton, B.J., McGuire, J.M., Sommerville, D.R., Dabisch, P.A., Jakubowski, E.M., Jr., Matson, K.L., Crouse, C.L. et al. (2006b). Effects of whole-body VX vapor exposure on lethality in rats. Inhal. Toxicol.18: 1091-9.
21. Benton, B.J., McGuire, J.M., Sommerville, D.R., Dabisch, P.A., Jakubowski, E.M., Jr., Crosier, R.B., Mioduszewski, R.J. et al. (2007). Effects of whole-body VX vapor exposure on lethality in rats. Technical Report ECBC TR-525, US Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD.
22. Bide, R.W., Risk, D.J. (2000). Inhalation toxicity of aerosolized nerve agents. 1. VX revisited. Technical Report DRES TR 2000-063. Defence Research Establishment, Suffield, Alberta, Canada.
23. Bide R.W., Risk D.J. Inhalation toxicity in mice exposed to sarin (GB) for 20-720 min. J. Appl. Toxicol. 2004, 24:459-467.
24. Bramwell E.C.B., Ladell W.S.S., Shephard R.J. Chemical and Biological Defence Establishment. Porton Down 1963, Salisbury, Wiltshire, UK, Human exposure to VX vapour. PTP 830.
25. Britton, K.B., Grant, C.L. (1988). Prediction of octanol-water partition coefficients of organophosphates. Evaluation of structure-function relationships. Special Report 88-11. US Department of the Army, Corps of Engineers Cold Regions Research and Engineering Laboratory, Hanover, NH.
26. Bruckner J.V., Keys D.A., Fisher J.W. The acute exposure guideline (AEGL) program: applications of physiologically based pharmacokinetic modeling. J. Toxicol. Environ. Health, Part A 2004, 67:621-634.
27. Bucci, T.J., Parker, R.M., Crowell, J.A., Thurman, J.D., Gosnell, P.A. (1992a). Toxicity studies on agents GA (phase II): 90-day subchronic study of GA (tabun) in CD rats. Final report. Prepared by the National Center for Toxicological Research, Jefferson, AR, for the US Department of the Army, Biomedical Research and Development Laboratory, Fort Detrick, MD.
28. Bucci, T.J., Parker, R.M., Gosnell, P.A. (1992b). Toxicity studies on agents GB and GD (phase II): 90-day subchronic study of GD (soman) in CD rats. Final report (FDA 224-85-0007). Prepared by the National Center for Toxicological Research, Jefferson, AR, for the US Department of the Army, Biomedical Research and Development Laboratory, Fort Detrick, MD.
29. Bucci, T.J., Fikes, J.D., Parker, R.M., Denny, K.H., Dacre, J.C. (1993). Developmental toxicity study (segment II: teratology) of tabun in CD rats and New Zealand white rabbits. Prepared for the US Department of the Army, Medical Research and Development Command, Fort Detrick, MD.
30. Buckles L.C. The hydrolysis rate of G agents. Report TCIR 393, US Army Chemical Research and Development Laboratory 1947, Army Chemical Center, MD, December 1947.
31. Callaway S., Dirnhuber P. Estimation of the concentration of nerve agent vapour required to produce measured degrees of miosis in rabbit and human eyes. Technical Paper No. 64. Chemical Defence Research Establishment, Porton Down, Salisbury, Wiltshire, UK 1971.
32. Cannard K. The acute treatment of nerve agent exposure. J. Neurol. Sci. 2006, 249:86-94.
33. Carnes S.A. Disposing of chemical weapons: a desired end in search of an acceptable means. Environ. Prof 1989, 11:279-290.
34. Carroll, N.C., Hoskin, F.C.G., McPhail, M.K., Myers, D.K. (1957). Vapour toxicity of VE and VX to female mice. STP 121. Suffield Experimental Station, Alberta, Canada.
35. Chanda S.M., Lassiter T.L., Moser V.C., Barone S., Padilla S. Tissue carboxylesterases and chlorpyrifos toxicity in the developing rat. Hum. Ecol. Risk Assess. 2002, 8:75-90.
36. Chebabo S.R., Santos M.D., Albuquerque E.X. The organophosphate sarin, at low concentrations, inhibits the evoked release of GABA in rat hippocampal slices. Neurotoxicology 1999, 20:871-882.
37. Chemical Stockpile Emergency Preparedness Program (CSEPP) (2003). Adoption of Acute Exposure Guideline Levels (AEGLs). Policy Paper No. 20 (revised). Department of the Army and Federal Emergency Management Agency, Chemical Stockpile Emergency Preparedness Program (February 2003). Accessible through. http://www.csepp-planners.net//CSEPP/hazard/hazard_aegl_policy_papers.as px.
38. Chemical Stockpile Emergency Preparedness Program (CSEPP) (2006a). CSEPP Planning Guidance. IEM/TEC05-05. CSEPP Planning Guidance Steering Committee. Department of the Army and Department of Homeland Security, Chemical Stockpile Emergency Preparedness Program (March 2006). Accessible through. http://www.csepportal.net.
39. Chemical Stockpile Emergency Preparedness Program (CSEPP) (2006b). CSEPP Programmatic Guidance. IEM/TEC05-05. CSEPP Planning Guidance Steering Committee. Department of the Army and Department of Homeland Security, Chemical Stockpile Emergency Preparedness Program (March 2006). Accessible through. http://www.csepportal.net.
40. Cicmanec J.L., Dourson M.L., Hertzberg R.C. Noncancer risk assessment. Toxicology and Risk Assessment: Principles, Methods, and Applications 1996, 293-310. Marcel Dekker, New York, NY, present and emerging issues. A.M. Fan, L.W. Chang (Eds.).
41. Clark D.N. Review of reactions of chemical agents in water. AD-A213 287 1989, Defense Technical Information Center, Alexandria, VA.
42. Conn C.A., Dokladny K., Menache M.G., Barr E.B., Kozak W., Kozak A., Wachulec M., et al. Effects of sarin on temperature and activity of rats as a model for Gulf War Syndrome neuroregulatory function. Toxicol. Appl. Pharmacol. 2002, 184:77-81.
43. Craig A.B., Woodson G.S. Observations on the effects of exposure to nerve gas, I: Clinical observations and cholinesterase depression. Am. J. Med. Sci. 1959, 238:13-17.
44. Craig F.N., Cummings E.G., Sim V.M. Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX. J. Investig. Dermatol. 1977, 68:357-361.
45. Crook J.W., Hott P., Owens E.J., Cummings E.G., Farrand R.L., Cooper A.E. The effects of subacute exposures of the mouse, rat, guinea pig, and rabbit, to low-level VX concentrations. Technical Report ARCSL-TR-82038, US Army Armament Research and Development Command 1983, Chemical Systems Laboratory, Aberdeen Proving Ground, MD.
46. Dabisch P.A., Miller D.B., Reutter S.A., Mioduszewski R.J., Thomson S.A. Miotic tolerance to sarin vapor exposure: role of the sympathetic and parasympathetic nervous systems. Toxicol. Sci. 2005, 85:1041-1047.
47. Dabisch, P.A., To, F., Kerut, E.K, Horsmon, M.S., Mioduszewski, R.J. (2007a). Multiple exposures to sarin vapor result in parasympathetic dysfunction in the eye but not the heart. Toxicol. Sci.99: 354-61.
48. Dabisch, P.A., Horsmon, M.S., Muse, W.T., Mioduszewski, R.J., Thomson, S.A. (2007b). Muscarinic receptor dysfunction induced by exposure to low levels of soman vapor. Toxicol. Sci.100: 281-9.
49. Dabisch, P.A., Hulet, S.W., Kristovich, R., Mioduszewski, R.J. (2008a). Inhalation toxicology of nerve agents. In Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics (J.A. Romano, Jr., B.J. Lukey, H. Salem, eds), pp. 233-46. CRC Press, Boca Raton, FL.
50. Dabisch, P.A., Davis, E.A., Renner, J.A., Jakubowski, E.M., Mioduszewski, R.J., Thomson, S.A. (2008b). Biomarkers of low-level exposure to soman vapor: comparison of fluoride regeneration to acetylcholinesterase inhibition. Inhal. Toxicol.20: 149-56.
51. Dawson R.M. Review of oximes available for treatment of nerve agent poisoning. J. Appl. Toxicol. 1994, 14:317-331.
52. De Jong L.P.A., Wolring G.Z. Effect of 1-(AR)alkyl-2-hydroxyimino methyl-pyridium salts on reactivation and aging of actylcholinesterase inhibited by ethyl dimethylphosphor-amidocyanidate (tabun). Biochem. Pharmacol 1978, 27:2229-2235.
53. Denk J.R. Effects of GB on mammalian germ cells and reproductive performance. EB-TR-74087. US Department of the Army 1975, Edgewood Arsenal, Aberdeen Proving Ground, MD.
54. Department of the Army (DA) Edgewood Arsenal Special Report, EO-SR-74001. US Department of the Army, Edgewood Arsenal, Aberdeen Proving Ground, MD. Chemical Agent Data Sheets 1974, Vol. 1.
55. Department of the Army (DA) Material safety data sheets: lethal nerve agents GA, GB, VX. US Department of the Army. Edgewood Research 1992, Development and Engineering Center, Aberdeen Proving Ground, MD.
56. Department of the Army (DA) (1990a). Occupational health guidelines for evaluation and control of occupational exposure to nerve agents GA, GB, GD and VX. DA Pam 40-8. US Department of the Army, Headquarters, Washington, DC.
57. Department of the Army (DA) (1990b). Potential military chemical/biological agents and compounds. Field Manual FM 3-9 (NAVFAC P-467, AFR 355-7). Headquarters, Department of the Army, Department of the Navy, Department of the Air Force, Washington, DC.
58. Department of the Army (DA) (2005). Potential Military Chemical/Biological Agents and Compounds. Field Manual (FM) 3-11.9. Army, Marine Corps, Navy, Air Force Multiservice Tactics, Techniques and Procedures. Available at Army Knowledge Online. http://www.us.army.mil.
59. Department of Defense (DOD) (2008). Department of Defense Dictionary of Military and Associated Terms (as amended through March 4, 2008). JP 1-02. http://www.dtic.mil/doctrine/jel/new_pubs/jpl_02.pdf.
60. De WolffF.A., Treijtel N., Vermeulen M. Mechanisms of peripheral neurotoxicity. Site-Selective Neurotoxicity 2002, 282-303. Taylor and Francis, New York, NY, Chapter 15. D.S. Lester, W. Slikker, P. Lazarovici (Eds.).
61. Dourson M.L. Methods for estimating oral reference doses (RfDs). Risk Assessment of Essential Elements 1994, 51-61. ILSI Press, Washington, DC. W. Mertz, C.O. Abernathy, S.S. Olin (Eds.).
62. Dunn M.A., Sidell F.R. Progress in the medical defense against nerve agents. JAMA 1989, 262:649-652.
63. Dunn M.A., Hackley B.E., Sidell F.R. Pretreatment for nerve agent exposure. In Medical Aspects of Chemical and Biological Warfare. Office of the Surgeon General 1997, 181-196. Walter Reed Army Medical Center, Washington, DC. F.R. Sidell, E.T. Takafuji, D.R. Franz (Eds.).
64. Dutreau C.W., McGrath F.P., Bray E.H. Median lethal concentration by inhalation in pigeons, rabbits, rats, and mice. 2. Median detectable concentration by odor for man 1950, Toxicity studies on GD. 1MDRR 8, CMLEM-52. Chemical Corps, Medical Division, Army Chemical Center, MD (ADE 470029 058).
65. Ehrich M., Jortner B.S. Organophosphorous-induced delayed neuropathy. Handbook of Neurotoxicity 2002, Vol. 1:17-25. Humana Press, Totowa, Chapter 2. E.J. Massaro (Ed.).
66. Eyer P.A., Worek F. Oximes. Chemical Warfare Agents: Toxicology and Treatment 2007, 305-329. John Wiley and Sons, Chichester, UK. 2nd edition. T.C. Marrs, R.L. Maynard, F.R. Sidell (Eds.).
67. Fairley A., Mumford S.A. Detection of the G gases by smell. PTP 74, Chemical Defence Research Establishment. Porton Down 1948, Salisbury, Wiltshire, UK.
68. Fonnum F., Sterri S.H. Tolerance development to toxicity of cholinesterase inhibitors. Toxicology of Organophosphate and Carbamate Compounds 2006, 257-267. Elsevier Academic Press, San Diego, CA. R.C. Gupta (Ed.).
69. Gall D. The use of therapeutic mixtures in the treatment of cholinesterase inhibition. Fundam. Appl. Toxicol. 1981, 1:214-216.
70. Gates M., Renshaw B. Fluorophosphates and other phosphorous-containing compounds. In NDRC (National Defense Research Committee) Chemical Warfare Agents and Related Chemical Problems, Part I-II (Conant, J.B., Tolman, R.C., Chair and vice-Chair). National Defense Research Committee 1946, Vol. 1. Division 9, Washington, DC, pp. 131-55.
71. Genovese, R.F., Shippee, S.J., Bonnell, J., Benton, B.J., Mioduszewski, R.J. (2004). Evaluating performance effects of low-level inhalation exposure to nerve agents in rats. Proceedings for the Army Science Conference (24th) held in Orlando, FL, on November 29-December 2, 2004 (8 pp.).
72. Genovese R.F., Benton B.J., Shippee S.J., Jakubowski E.M., Bonnell J.C. Effects of low-level inhalation exposure to cyclosarin on learned behaviors in Sprague-Dawley rats. J. Toxicol. Environ. Health, Part A 2006, 69:2167-2180.
73. Genovese R.F., Benton B.J., Lee E.H., Shippe S.J., Jakubowski E.M. Behavioral and biochemical evaluation of sub-lethal inhalation exposure to VX in rats. Toxicology 2007, 232:109-118.
74. Genovese R.F., Benton B.J., Oubre J.L., Fleming P.J., Jakubowski E.M., Mioduszewski R.J. Determination of miosis threshold from whole-body vapor exposure to sarin in African green monkeys. Toxicology 2008, 244:123-132.
75. Goldman, M., Klein, A.K., Kawakami, T.G., Rosenblatt, L.S. (1987). Toxicity studies on agents GB and GD. DTIC (AD A187841). Laboratory for Energy-Related Health Research, Prepared for the US Department of the Army, Medical Research and Development Command, Fort Detrick, MD.
76. Goldman M., Wilson B.W., Kawakami T.G., Rosenblatt L.S., Culberson M.R., Schreider J.P., Remsen J.F., Shifrine M. Toxicity studies on agent VX. DTIC (AD A201397). Laboratory for Energy-Related Health Research, Prepared for the US Department of the Army, Medical Research and Development Command, Fort Detrick, MD 1988.
77. Gordon J.J., Inns R.H., Johnson M.K., Leadbeater L., Maidment M.P., Upshall D.G., Cooper G.H., et al. The delayed neuropathic effects of nerve agents and some other organophosphorous compounds. Arch. Toxicol. 1983, 52:71-82.
78. Gordon R.K. Rapid decontamination of chemical warfare agents. Handbook of the Toxicology of Chemical Warfare Agents 2009, Elsevier, San Diego, CA. R. Gupta (Ed.).
79. Grob D. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterases compounds. Arch. Intern. Med. 1956, 98:221-239.
80. Grob D., Harvey A.M. The effects and treatment of nerve gas poisoning. Am. J. Med. 1953, 14:52-63.
81. Grob D., Harvey J.C. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J. Clin. Invest 1958, 37:350-368.
82. Harris L.W., Heyl W.C., Stitcher D.L., Broomfield C.A. Effects of 1,1-oxydimethylene-bis-(4-tert-butyl pyridinium chloride) (SAD-128) and decamethonium on reactivation of soman-and sarin-inhibited cholinesterase by oximes. Biochem. Pharmacol 1978, 27:757-761.
83. Harvey J.C. Clinical observations on volunteers exposed to concentrations of GB. Medical Laboratories Research Report No. 114, Publication Control No. 5030-114 (CMLRE-ML-52). Medical Laboratories, Army Chemical Center, MD 1952.
84. Holmstedt B. Pharmacology of organophosphorous cholinesterase inhibitors. Pharmacol. Rev. 1959, 11:567-688.
85. Hulet, J.S., Sommerville, D.R., Crosier, R.B., Dabisch, P.A., Miller, D.B., Benton, B.J., Forster, J.S. et al. (2006a). Comparison of low-level sarin and cyclosarin vapor exposure on pupil size of the Göttingen minipig: effects of exposure concentration and duration. Inhal. Toxicol.18: 143-53.
86. Hulet, S.W., Sommerville, D.R., Jakubouwski, E.M., Benton, B.J., Forster, J.S., Dabisch, P.A., Scotto, J.A. et al. (2006b). Estimating lethal and severe toxic effects in minipigs following 10, 60, and 180 minutes of whole-body GB vapor exposure. ECBC-TR-451. Edgewood Chemical Biological Center, Research and Technology Directorate, Aberdeen Proving Ground, MD.
87. Hulet S.W., Sommerville D.R., Benton B.J., Forster J.S., Scotto J.A., Muse W.T., Crosier R.B., et al. Low-level sarin (GF) vapor exposure in the Göttingen minipig: effects of exposure concentration and duration on pupil size. ECBC-TR-450. Edgewood Chemical Biological Center, Research and Technology Directorate, Aberdeen Proving Ground, MD 2006.
88. Hulet S.W., Sommerville D.R., Benton B.J., Forster J.S., Scotto J.A., Muse W.T., Crosier R.B., et al. Low-level cyclo-sarin (GF) vapor exposure in the Göttingen minipig: effects of exposure concentration and duration on pupil size. ECBC-TR-452. Edgewood Chemical Biological Center, Research and Technology Directorate, Aberdeen Proving Ground, MD 2007.
89. Inns R.H., Leadbeater L. The efficacy of bispyridinium derivatives in the treatment of organophosphate poisoning in the guinea pig. J. Pharm. Pharmacol. 1983, 35:427-433.
90. Jimmerson V.R., Shih T.-M., Mailman R.B. Variability in soman toxicity in the rat: correlation with biochemical and behavioral measures. Toxicology 1989, 57:241-254.
91. Johns R.J. The effect of low concentrations of GB on the human eye. Research Report No. 100, Publication Control No. 5030-100 (CMLRE-ML-52). Chemical Corps Medical Laboratories, Army Chemical Center, MD 1952.
92. Kassa J., Pecka M., Tichý M., Bajgar J., Koupilová M., Herink J., KrocÏová Z. Toxic effects of sarin in rats at three months following single and repeated low-level inhalation exposure. Pharmacol. Toxicol. 2001, 88:209-212.
93. Kassa J., KrecÏová Z., Skopec F., Herink J., Bajgar J., Ševelová L., Tichý M., et al. The influence of sarin on various physiological functions in rats following single or repeated low-level inhalation exposure. Inhal. Toxicol. 2004, 16:517-530.
94. Koelle G.B. Anticholinesterase agents. The Pharmacological Basis of Therapeutics 1975, 445-466. Macmillan, New York, NY. 5th edition. L.S. Goodman, A. Gilman (Eds.).
95. Koelle G.B. Organophosphate poisoning -an overview. Fundam. Appl. Toxicol 1981, 1:129-134.
96. Koelle G.B. Pharmacology of organophosphates. J. Appl. Toxicol 1994, 14:105-109.
97. Koon W.S., Cresthull P., Crook J.W., et al. Odor detection of VX vapor with and without a stabilizer. Chemical Warfare Laboratory Report, No. 2292 1959, Aberdeen Proving Ground, MD.
98. Koon, W.S., Crook, J.W., Oberst, F.W. (1960). Progress report on the toxicity of VX vapor to mice and goats. Army Chemical Warfare Laboratories Report, No. TM 24-37. Army Chemical Center, MD.
99. Krewski D., Bakshi K., Garrett R., Falke E., Rusch G., Gaylor D. Development of acute exposure guideline levels for airborne exposures to hazardous substances. Regul. Toxicol. Pharmacol. 2004, 39:184-201.
100. Laborde, J.B., Bates, H.K. (1986). Developmental toxicity study of agent GB-DCSM Types I and II in CD rats and NZW rabbits. Final Report. AD-A168 331. National Center for Toxicological Research, Jefferson, AR.
101. LaBorde J.B., Bates J.K., Dacre J.C., Young J.F. Developmental toxicity of sarin in rats and rabbits. J. Toxicol. Environ. Health 1996, 47:249-265.
102. Lallement, G., Carpenteir, P., Pernot-Marino, I., Baubichon, D., Collet, A., Blanchet, G. (1991a). Involvement of the different rat hippocampal glutamatergic receptors in development of seizures induced by soman. Neurotoxicology4: 655-64.
103. Lallement, G., Carpenteir, P., Collet, A., Pernot-Marino, I., Baubichon, D., Blanchet, G. (1991b). Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus. Brain Res.563: 234-340.
104. Lallement G., Reanault F., Baubichon D., et al. Compared efficacy of diazepam or avizafone to prevent soman-induced electroencephalographic disturbances and neuropathology in primates: relationship to plasmic benzodiazepine pharmacokinetics. Arch. Toxicol. 2000, 74:480-486.
105. Lallement G., Masqueliez C., Baubichon D., et al. Protection against soman-induced lethality of the antidote combination atropine-pralidoxime pro-diazepam packed as freeze-dried form. J. Med. Chem. 2004, 2:1-11.
106. Leadbeater L., Inns R.H., Rylands J.M. Treatment of poisoning by soman. Fundam. Appl. Toxicol. 1985, 5:5225-5231.
107. Leikin J.B., Thoman R.G., Walter F.G., Klein R., Meislin H.W. A review of nerve agent exposure for the critical care physician. Crit. Care Med. 2002, 30:2346-2354.
108. Lenz D.A., Broomfield C.A., Yeung D.T., Masson P., Maxwell D.M., Cerasoli D. Nerve agent bioscavengers: progress in development of new mode of protection against organophosphorous exposure. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 175-202. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
109. Lillibridge, S. (1995). United States Medical Delegation to Japan. Trip Report (25 April 1995). From S.R. Lillibridge, Acting Chief, Disaster Assessment and Epidemiology Section, to R.J. Jackson, Director, National Center for Environmental Health, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA.
110. Marrs, T.C. (2007). Toxicology of organophosphate nerve agents. In Chemical Warfare Agents: Toxicology and Treatment, 2nd edition (T.C. Marrs, R.L. Maynard, F.R. Sidell, eds), pp. 191-221. John Wiley and Sons, Chichester, UK.
111. Marrs, T.C., Sellström, Å. (2007). The use of benzodiazepines in organophosphate nerve agent intoxication. In Chemical Warfare Agents: Toxicology and Treatment, 2nd edition (T.C. Marrs, R.L. Maynard, F.R. Sidell, eds), pp. 331-41. John Wiley and Sons, Chichester, UK.
112. Marrs T.C., Rice P., Vale J.A. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol. Rev. 2006, 25:297-323.
113. Martin L.J., Doebler J.A., Shih T.-M., et al. Protective effect of diazepam pretreatment on soman-induced brain lesion formation. Brain Res. 1985, 325:287-289.
114. Maxwell D.M., Brecht K.M. Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphate compounds. J. Appl. Toxicol. 2001, 21:S103-S107.
115. Maxwell D.M., Brecht K.M., O'Neill B.M. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol. Lett. 1987, 39:35-42.
116. McDonough J.H., Romano J.A. Health effects of low-level exposure to nerve agents. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 71-96. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
117. McGrath F.P., Von Berg V.J., Oberst F.W. Toxicity and perception of GF vapor. Medical Laboratory Research Report, MLRR 185, Army Chemical Center, MD 1953.
118. McKee W.H.E., Woolcott B. Report on exposures of unprotected men and rabbits to low concentrations of nerve gas vapour. PRP-143. Chemical Defence Research Establishment, Porton Down, Salisbury, Wiltshire, UK 1949.
119. McNamara B.P., Leitnaker F. Toxicological basis for controlling emission of GB into the environment. Edgewood Arsenal Special Publication 100-98. Department of the Army, Medical Research Laboratory, Edgewood Arsenal, Aberdeen Proving Ground, MD 1971.
120. Meshulam Y., Davidovici R., Wengier A., Levy A. Prophylactic transdermal treatment with physiostigmine and scopoloamine against soman intoxication in guinea-pigs. J. Appl. Toxicol. 1995, 15:263-266.
121. Mioduszewski, R.J., Reutter, S.A., Miller, L.L., Olajos, E.J., Thomson, S.A. (1998). Evaluation of airborne exposure limits for G-agents: occupational and general population exposure criteria. ERDEC-TR-489. Edgewood Research Development and Engineering Center, Aberdeen Proving Ground, MD.
122. Mioduszewski, R.J., Manthei, J., Way, R., Burnett, D., Gaviola, B., Muse, W., Anthony, J., Durst, D., Sommerville, D., Crosier, R., Thomson, S., Crouse, C. (2001). ECBC low level operational toxicology program: Phase I-B inhalation toxicity of sarin vapor in rats as a function of exposure concentration and duration. ECBC-TR-183. Edgewood Research Development and Engineering Center, Aberdeen Proving Ground, MD.
123. Mioduszewski, R.J., Manthei, J., Way, R., Burnett, D., Gaviola, B., Muse, W., Thomson, S. et al. (2002a). Low-level sarin vapor exposure in rats: effect of exposure concentration and duration on pupil size. ECBC-TR-235. Edgewood Chemical Biological Center, US Army Soldier and Biological Chemical Command, Aberdeen Proving Ground, MD.
124. Mioduszewski, R.J., Manthei, J., Way, R., Burnett, D., Gaviola, B., Muse, W., Thomson, S. et al. (2002b). Interaction of exposure concentration and duration in determining acute toxic effects of sarin vapor in rats. Toxicol. Sci.66: 176-84.
125. Morita H., Yanagisawa N., Nakajima T., Shimizu M., Hirabayashi H., Okudera H., Nohara M., et al. Sarin poisoning in Matsumoto, Japan. Lancet 1995, 346:290-293.
126. Munro N.B., Ambrose K.R., Watson A.P. Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ. Health Perspect 1994, 102:18-38.
127. Nambiar M., Gordon N.K., Rezk P.E., Katos A.M., Wajda N.A., Moran T.S., Steele K.E., Doctor B.P., Sciuto A.M. Medical countermeasures against respiratory toxicity and acute lung injury following inhalation exposure to chemical warfare nerve agent VX. Toxicol. Appl. Pharmacol. 2007, 219:142-150.
128. National Research Council (NRC), Committee on Toxicology, Subcommittee on Chronic Reference Dose for Chemical Warfare Agents Review of the US Army's Health Risk Assessment for Oral Exposure to Six Chemical Warfare Agents 1999, National Academy Press, Washington, DC.
129. National Research Council (NRC), Committee on Toxicology, Subcommittee on Acute Exposure Guideline Levels Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals 2001, National Academy Press, Washington, DC.
130. National Research Council (NRC) Committee on Toxicology, Board on Environmental Studies and Toxicology. Acute Exposure Guideline Levels for Selected Airborne Chemicals 2003, Vol. 3. The National Academies Press, Washington, DC, Commission on Life Sciences.
131. National Research Council (NRC) Committee on Toxicology, Board on Environmental Studies and Toxicology. Acute Exposure Guideline Levels for Selected Airborne Chemicals 2007, Vol. 5. The National Academies Press, Washington, DC, Commission on Life Sciences.
132. National Response Team (NRT) (2008). Chemical Quick Reference Guides. US National Response Team (February 2008). http://www.nrt.org/.
133. National Security Decision Memorandum 35 United States policy on chemical warfare program and bacteriological/biological research program 1969, National Security Council, Washington, DC.
134. Nozaki H., Hori S., Shinozawa Y., Fujishima S., Takuma K., Kimura H., Suzuki M., et al. Relationship between pupil size and acetylcholinesterase activity in patients exposed to sarin vapor. Intensive Care Med. 1997, 23:1005-1007.
135. Oberst F.W., Koon W.S., Christensen M.K., Crook J.W., Cresthull P., Freeman G. Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man. Clin. Pharmacol. Ther 1968, 9:421-427.
136. O'Callahan J.P. Neurotoxic esterase: not so toxic?. Nat. Genet. 2003, 33:1-2.
137. Office of the Assistant Secretary of the Army (OASA) (1999) Derivation of Health-Based Environmental Screening Levels (HBESL) for Chemical Warfare Agents. Memorandum signed by Raymond J. Fatz, Deputy Assistant Secretary of the Army. Department of the Army, Office of the Assistant Secretary (Environment, Safety, and Occupational Health) May 28, 1999, Army Pentagon, Washington, DC.
138. Ohbu S., Yamashina A., Takasu N. Sarin poisoning on Tokyo subway. South. Med. J 1997, 90:587-593.
139. Okumura T., Takasu N., Ishimatu S., Miyanoki S., Mitsuhashi A., Kumada K., Tanaka K., et al. Report on 640 victims of the Tokyo subway sarin attack. Ann. Emerg. Med 1996, 28:129-135.
140. Okumura T., Nomura T., Suzuki T., Sugita M., Takeuchi Y., Naito T., Okumora S., et al. The dark morning: the experiences and lessons learned from the Tokyo subway sarin attack. Chemical Warfare Agents: Toxicology and Treatment 2007, 277-303. John Wiley and Sons, Chichester, UK. 2nd edition. T.C. Marrs, R.L. Maynard, F.R. Sidell (Eds.).
141. Opresko D.M., Young R.A., Faust R.A., Talmage S.S., Watson A.P., Ross R.H., Davidson K.A., et al. Chemical warfare agents: estimating oral reference doses. Rev. Environ. Contam. Toxicol 1998, 156:1-183.
142. Opresko D.M., Young R.A., Watson A.P., Faust R.A., Talmage S.S., Ross R.H., Davidson K.A., et al. Chemical warfare agents: current status of oral reference doses. Rev. Environ. Contam. Toxicol 2001, 172:65-85.
143. Pereira, E.F.R., Burt, D.R., Aracava, Y., Kan, R.K., Hamilton, T.A., Romano, J.A., Jr., Adler, M. et al. (2008). Novel medical countermeasure of organophosphorous intoxication: connection to Alzheimer's disease and
144. Podoly E., Diamant S., Friedler A., Livnah O., Soreq H. Butyrylcholinesterase and its synthetic C-terminal peptide confer in vitro suppression of amyloid fibril formation. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 203-218. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
145. Pope C. Organophosphorous pesticides: do they all have the same mechanism of toxicity?. J. Toxicol. Environ. Health, Part B 1999, 2:161-181.
146. Pope C., Liu J. Handbook of Neurotoxicology. Nonesterase actions of anticholinesterase insecticides 2002, Vol. 1:29-43. Humana Press, Totowa, NJ. E.J. Massaro (Ed.).
147. Pulley S.A., Jones M.R. Emergency medical response to a chemical terrorist attack. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 675-711. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
148. Radilov A., et al. Russian VX: toxicity, risk exposure and hygienic regulations. Handbook of Toxicology of Chemical Warfare Agents 2009, 69-91. Elsevier, San Diego, CA. R. Gupta (Ed.).
149. Rao K.S., Aracava Y., Rickett D.L., Albuquerque E.X. Noncompetitive blockade of the nicotinic acetylcholine receptor-ion channel complex by an irreversible cholinesterase inhibitor. J. Pharmacol. Exp. Ther 1987, 240:337-344.
150. Reutter S.A., Mioduszewski R.J., Thomson S.A. Evaluation of airborne exposure limits for VX: worker and general population exposure criteria. ECBC-TR-074. Edgewood Chemical Biological Center, US Army Soldier and Biological Chemical Command, Aberdeen Proving Ground, MD 2000.
151. Rocha E.S., Chebabo S.R., Santos M.D., Aracava Y., Albuquerque E.X. An analysis of low level doses of cholinesterase inhibitors in cultured neurons and hippocampal slices of rats. Drug Chem. Toxicol 1998, 21(Suppl. 1):191-200.
152. Rocha E.S., Santos M.D., Chebabo S.R., Aracava Y., Albuquerque E.X. Low concentrations of the organophosphate VX affect spontaneous and evoked transmitter release from hippocampal neurons: toxicological relevance of cholinesterase-dependent actions. Toxicol. Appl. Pharmacol 1999, 159:31-40.
153. Rubin L.S., Goldberg M.N. Effect of sarin on dark adaptation in man: threshold changes. J. Appl. Physiol 1957, 11:439-444.
154. Rubin L.S., Krop S., Goldberg M.N. Effect of sarin on dark adaptation in man: mechanism of action. J. Appl. Physiol 1957, 11:445-449.
155. Saxena A., Luo C., Chilukuri N., Maxwell D.M., Doctor B.P. Novel approaches to medical protection against chemical warfare nerve agents. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 145-173. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
156. Schreider J.P., Rowland J.R., Rosenblatt L.S., Hendrick A.G. The teratology effects of VX in rats. Draft Final Report. Laboratory for Energy-Related Health Effects Research. Prepared for US Army Medical Bioengineering Research and Development Laboratory 1984, University of California, Fort Detrick, MD, Davis, CA.
157. Schreider J.P., Remsen J.F., Shifrine M. Toxicity studies on agent VX. Final Report (AD A201397). Prepared by the Laboratory for Energy-Related Health Effects Research. Davis, CA, for the US Department of the Army, Medical Research and Development Command 1988, University of California, Fort Detrick, MD.
158. Scott, L. (2007). Pretreatment for nerve agent poisoning. In Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics (J.A. Romano, Jr., B.J. Lukey, H. Salem, eds), pp. 343-53. CRC Press, Boca Raton, FL.
159. Sekowski, J.W., Orehek, M.A., Bucher, J. et al. (2004). Low-level inhalation exposure to chemical nerve agent vapor induces expression of neuronal apoptosis and regeneration genes. Proceedings of the 24th Annual Army Science Conference, November 29-December 2, 2004, Orlando, FL.
160. Shih T.-M., Doniho S.M., McDonough J.H. Control of nerve-agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 2003, 188:69-80.
161. Shih T.-M., Hulet S.W., McDonough J.H. The effects of repeated low-dose sarin exposure. Toxicol. Appl. Pharm. 2006, 215:119-134.
162. Sidell F.R. Clinical considerations in nerve agent intoxication. Chemical Warfare Agents 1992, 155-194. Academic Press, New York, NY. S.M. Somani (Ed.).
163. Sidell F.R. Chemical agent terrorism. Ann. Emerg. Med. 1996, 28:223-224.
164. Sidell F.R. Medical Aspects of Chemical and Biological Warfare. Office of the Surgeon General 1997, 129-179. Walter Reed Army Medical Center, Washington, DC, Nerve agents. F.R. Sidell, E.T. Takafuji, D.R. Franz (Eds.).
165. Sidell F.R., GroffW.A. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol. Appl. Pharmacol 1974, 27:241-252.
166. Sim V.M. Effect on pupil size of exposure to GB vapour. Porton Technical Paper 531. Chemical Defence Experimental Establishment, Directorate of Chemical Defence Research and Development, Porton Down, Salisbury, Wiltshire, UK 1956.
167. Small, M.J. (1984). Compounds formed from the chemical decontamination of HD, GB, and VX and their environmental fate. Technical Report 8304 (DTIC: AD A149515). US Department of the Army, Medical Bioengineering Research and Development Laboratory, Fort Detrick, MD.
168. Somani S.M., Husain K. Low-level nerve agent toxicity under normal and stressful conditions. Chemical Warfare Agents: Toxicity at Low Levels 2001, 83-120. CRC Press, Boca Raton, FL. S.M. Somani, J.A. Romano (Eds.).
169. Sommerville D.R., Park K.H., Kierzewski M.O., Dunkell M.D., Hutton M.I., Pinto N.A. Toxic load modeling. Inhalation Toxicology 2006, CRC Press, Boca Raton, FL. 2nd edition. S.A. Katz, H. Salem (Eds.).
170. Storm J.E., Rozman K.K., Doull J. Occupational exposure limits for 30 organophosphate pesticides based on inhibition of red blood cell cholinesterase. Toxicology 2000, 150:1-29.
171. Ten Berge W.F., Zwart A., Appelman L.M. Concentration-time mortality response relationship of irritant and systemically acting vapours and gases. J. Hazard. Mater. 1986, 13:301-309.
172. Tevault D.E., Buchanan J.H., Buettner L.C. Vapor pressure of cyclohexylmethylphosphonofluoridate (GF). ECBC-TR-304. Edgewood Chemical Biological Center, US Department of the Army, Aberdeen Proving Ground, MD 2003.
173. Tu A.T. Toxicological and chemical aspects of sarin terrorism in Japan in 1994 and 1995. Toxin Rev. 2007, 26:231-274.
174. Tucker, M., Raber, E. (2008). Facility restoration following chemical contamination -Operational Technology Demonstration (OTD) overview. Proceedings of 2008 Annual Chemical and Biological/R&D Technologies Conference, San Antonio, TX, January 28-February 1, 2008.
175. US Army Center for Health Promotion and Preventive Medicine (USACHPPM) (1999). Derivation of health-based environmental screening levels for chemical warfare agents: a technical evaluation. US Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD.
176. US Army Center for Health Promotion and Preventive Medicine (USACHPPM) (2004). Chemical exposure guidelines for deployed military personnel. USACHPPM Technical Guide 230 (v. 1.3, with January 2004 addendum). US Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD.
177. US Army Center for Health Promotion and Preventive Medicine (USACHPPM) Health-based chemical vapor concentration levels for future systems acquisition and development. USACHPPM Technical Report No. 64-FF-07Z2-07. US Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD 2008.
178. US Environmental Protection Agency (USEPA) (1989). Risk assessment guidance for superfund, Vol. 1. Human Health Evaluation Manual (Part A). EPA/540/1-89/002. Office of Emergency and Remedial Response, USEPA, Washington, DC.
179. US Environmental Protection Agency (USEPA) Acute and 28-day delayed neurotoxicity of organophosphorous substances. EPA 712-C-98-237. Office of Prevention. Pesticides and Toxic Substances 1998, US Environmental Protection Agency, Washington, DC, Health effects test guidelines: OPPTS 870.6100.
180. US Environmental Protection Agency (USEPA) Office of Pesticide Programs science policy on the use of data on cholinesterase inhibition for risk assessment of organophosphorus and carbamate pesticides. Office of Pesticide Programs. DC 2000, US Environmental Protection Agency, Washington.
181. Vale J.A., Rice P., Marrs T.C. Managing civilian casualties affected by nerve agents. Chemical Warfare Agents: Toxicology and Treatment 2007, 249-276. John Wiley and Sons, Chichester, UK. 2nd edition. T.C. Marrs, R.L. Maynard, F.R. Sidell (Eds.).
182. Van der Schans M.J., Benshop H.P., Whalley C.E. Toxicokinetics of nerve agents. Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology and Therapeutics 2008, 97-122. CRC Press, Boca Raton, FL. J.A. Romano, B.J. Lukey, H. Salem (Eds.).
183. Van Helden H.P.M., Trap H.C., Oostdijk J.P., Kuipers W.C., Langenberg J.P., Benschop H.P. Long-term, low-level exposure of guinea pigs and marmosets to sarin vapor in air: lowest-observable-effect level. Toxicol. Appl. Pharmacol 2003, 189:170-179.
184. Van Helden, H.P.M., Trap, H.C., Kuipers, W.C., Oostdijk, J.P., Benschop H.P., Langenberg, J.P. (2004a). Low-level exposure of guinea pigs and marmosets to sarin vapour in air: lowest-observable-adverse-effect level (LOAEL) for miosis. J. Appl. Toxicol. 24: 59-68.
185. Van Helden, H.P.M., Trap, H.C., Kuijpers, W.C., Oostdijk, J.P., Benschop, H.P., Langenberg, J.P. (2004b). Low levels of sarin affect the EEG in marmoset monkeys: a pilot study. J. Appl. Toxicol. 24: 475-83.
186. Van Kampen K.R., Shupe J.L., Johnson A.E., James L.F., Smart R.A., Rasmussen J.E. Effects of nerve gas poisoning in sheep in Skull Valley, UT. J. Am. Vet. Med. Assoc. 1970, 156:1032-1035.
187. Walday P., Aas P., Fonnum F. Inhibition of serine esterases in different rat tissues following inhalation of soman. Biochem. Pharmacol. 1991, 41:151-153.
188. Watson, A., Opresko, D., Young, R., Hauschild, V. (2006a). Development and application of acute exposure guideline levels (AEGLs) for chemical warfare nerve and sulfur mustard agents. J. Toxicol. Environ. Health, Part B. 9: 173-263.
189. Watson, A.P., Bakshi, K., Opresko, D., Young, R., Hauschild, V., King, J. (2006b). Cholinesterase inhibitors as chemical warfare agents: community preparedness guidelines. In Toxicology of Organophosphate and Carbamate Compounds (R. Gupta, ed.), pp. 47-68. Elsevier Academic Press, San Diego, CA.
190. Watson, A.P., Dolislager, F.G. (2007). Reevaluation of 1999 Health-Based Environmental Screening Levels (HBESLs) for Chemical Warfare Agents. ORNL/TM-2007/080. Oak Ridge National Laboratory, Oak Ridge, TN 37831-6283 (May 2007).
191. Weimer J.T., McNamara B.P., Owens E.J., Cooper J.G., van de Wal A. Proposed revision of limits for human exposure to GB vapor in nonmilitary operations based on one-year exposures of laboratory animals to low airborne concentrations. ARCSL-TR-78056. US Army Armament Research and Development Command 1979, Chemical Systems Laboratory, Aberdeen Proving Ground, MD.
192. Wetherell J.R. Continuous administration of low dose ranges of physostigmine and hyoscine to guinea pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J. Pharm. Pharmacol. 1994, 46:1023-1038.
193. Wetherell J., Hall T., Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea pig. Neurotoxicology 2002, 23:341-345.
194. Wetherell J., Price M., Mumford H., Armstrong S., Scott L. Development of next generation medical countermeasures to nerve agent poisoning. Toxicology 2007, 233:120-127.
195. Whalley C.E., Benton B.J., Manthei J.H., Way R.A., Jakubowski E.M., Burnett D.C., Gaviola B.P., et al. Low-level cyclosarin (GF) vapor exposure in rats: effect of exposure concentration and duration on pupil size. ECBC-TR-407S (081004). US Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD 2004.
196. Whalley C.E., McGuire J.M., Miller D.B., Jakubowski E.M., Miodiuszewski R.J., Thomson S.A., Lumley L.A., et al. Kinetics of sarin (GB) following a single sublethal inhalation exposure in the guinea pig. Inhal. Toxicol. 2007, 19:667-681.
197. Willems J.L., Narcaise M., DeBisschop H.C. Delayed neuropathy by the organophosphorous nerve agents soman and tabun. Arch. Toxicol 1984, 55:76-77.
198. Wilson B.W., Henderson J.D., Kellner T.P., Goldman M., Higgins R.J., Dacre J.C. Toxicity of repeated doses of organophosphorous esters in the chicken. J. Toxicol. Environ. Health 1988, 23:115-126.
199. Wilson B.W., Kawakami T.G., Cone N., Henderson J.D., Rosenblatt L.S., Goldman M. Genotoxicity of the phosphoramidate agent tabun (GA). Toxicology 1994, 86:1-12.
200. Winrow C.J., Hemming M.L., Allen D.A., et al. Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. Nat. Genet. 2003, 33:477-485.
201. Yanagisawa N., Morita H., Nakajima T. Sarin experiences in Japan: acute toxicity and long-tem effects. J. Neurolog. Sci. 2006, 249:76-85.
202. Yang Y.-C. Chemical detoxification of nerve agent VX. Acc. Chem. Res. 1999, 32:109-115.
203. Young R.A., Opresko D.M., Watson A.P., Ross R.H., King J., Choudhury H. Deriving toxicity values for organophosphorous nerve agents. A position paper in support of the procedures and rationale for deriving oral RfDs for chemical warfare agents. Hum. Ecol. Risk Assess. 1999, 5:589-634.